There are so many surprising and wonderful D-stories out there. Sometimes you just have to share. Andy Tiedeman, a 28-year-old self-proclaimed “geek” from the DC area, was 13 years old when he was diagnosed. We found each other recently through the web, and his unusual campaign to raise awareness. Dodgeball for diabetes, really? (I hated that sport in school) But each one of us has to find our own way to cope, and to turn…Read more »
When the JDRF recently announced its newest artificial pancreas push — a partnership with Animas and Dexcom to actually develop a commercial product — head of the project Aaron Kowalski kindly agreed to answer reader questions here.
Today, I bring you those answers, direct “from the horses’ mouth,” as it were.
Q) How much more advanced will this be than the Medtronic Paradigm Veo system launched in Europe, which stops insulin delivery for…
I know, I know, I had the same reaction: What the heck?! Just on the heels of the Juvenile Diabetes Research Foundation (JDRF)’s big artificial pancreas announcement last week that brings the non-profit into a commercial partnership with J&J, yesterday they released news of a new commercial partnership with Becton Dickinson (BD). The goal of this collaboration is to improve insulin pump therapy.
I found the press release a bit confusing. The wording seemed to…
Very big news in the diabetes world today, Folks: the Juvenile Diabetes Research Foundation (JDRF) has announced a partnership with insulin pump makers Animas Corp. (a Johnson & Johnson company) to actually start building the first ready-for-market artificial pancreas, i.e. “a fully automated system to dispense insulin … based on real-time changes in blood sugar levels.” DexCom will provide the continuous glucose monitoring (CGM) technology for the new system being developed.
I was fortunate to…
At the end of last year (so, basically, two weeks ago), the Juvenile Diabetes Research Foundation announced a joint partnership with the Johnson & Johnson Corporate Office of Science and Technology to help with the discovery and development of drugs to promote beta cell survival. The program will look to fund research at academic centers around the world that could eventually lead to novel new drugs for the prevention and treatment of type 1 diabetes.…Read more »